Home of Fast Facts and Fast Fact CME - Palliative Care ...
FAST FACTS AND CONCEPTS #393CAR-T CELL IMMUNOTHERAPY: WHAT YOU NEED TO KNOWRamy Sedhom MD, Arjun Gupta MD, Areej El-Jawahri MDBackground: Immunotherapy using one’s own T-cells that are genetically engineered to express a chimeric antigen receptor (CAR) is an emerging therapy for hematologic and non-hematologic cancer. CAR-T cell therapy has induced rapid and durable clinical responses in otherwise fatal cancers, but is associated with unique, possibly severe, toxicities. This Fast Fact will discuss the basics of CAR-T cell therapy for clinicians, approved indications, and toxicities. CAR-T Cell Therapy: CAR T-cell therapy alters the function of a patient’s own T cells or those of a healthy donor, to recognize and kill cancer cells ADDIN EN.CITE <EndNote><Cite><Author>Brudno</Author><Year>2018</Year><RecNum>5683</RecNum><DisplayText>(1)</DisplayText><record><rec-number>5683</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1574802158" guid="849b9b81-5e8b-4873-a751-471b9c81ba4c">5683</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Brudno, J. N.</author><author>Kochenderfer, J. N.</author></authors></contributors><auth-address>Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH Building 10 room 3-3330, Bethesda, Maryland 20892, USA.</auth-address><titles><title>Chimeric antigen receptor T-cell therapies for lymphoma</title><secondary-title>Nat Rev Clin Oncol</secondary-title></titles><periodical><full-title>Nat Rev Clin Oncol</full-title></periodical><pages>31-46</pages><volume>15</volume><number>1</number><edition>2017/09/01</edition><keywords><keyword>Antigens, CD19/*immunology</keyword><keyword>Humans</keyword><keyword>Immunotherapy, Adoptive/*methods</keyword><keyword>Ki-1 Antigen/immunology</keyword><keyword>Lymphoma/*therapy</keyword><keyword>Receptors, Antigen, T-Cell/*immunology/therapeutic use</keyword></keywords><dates><year>2018</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1759-4782 (Electronic)
1759-4774 (Linking)</isbn><accession-num>28857075</accession-num><urls><related-urls><url>;(1). These tumor-targeted T cells are engineered in the laboratory, expanded to large numbers and infused back into the patient a few weeks after harvest. Once infused, the CAR-T cells divide and multiply, bypassing the barriers and incremental kinetics of active immunization, exerting both immediate and long-term anti-tumor effects. Patients who receive CAR T-cell therapy have a recovery/monitoring period of approximately 3-6 months. During this period, patients are evaluated for side effects and treatment response. Care is usually limited to specialty referral centers. While CAR T-cell therapy is being studied widely in solid tumors, such as prostate, breast, lung and colorectal cancer, the following are FDA-approved indications for CAR T-cell therapy:Tisagenlecleucel - children or adults 25 or younger with relapsed or refractory acute lymphoblastic leukemia.Axicabtageneciloleucel - Relapsed/Refractory large B-cell lymphoma despite ≥ 2 systemic therapies.CAR T-cells in the treatment of multiple myeloma were granted fast track designation by the FDA. Response Rates and Durable Remissions: Compared to historical controls, objective and complete response rates have been impressive in patients who have progressed on other treatments. Of 24 patients enrolled in a single institution trial of tisagenlecleucel, 46% of patients in the diffuse large b-cell cohort had a complete remission, while 71% of patients in the follicular lymphoma cohort had a complete response. These remissions were durable, with 60% of patients being relapse-free at 4 years ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1" ExcludeYear="1"><RecNum>5692</RecNum><DisplayText>(2)</DisplayText><record><rec-number>5692</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1574803341" guid="2afc8628-211d-4a8f-900d-a790f30e120c">5692</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Chong EA, Svoboda J, Nasta SD, et al. CD19‐directed car t cell therapy (CTL019) for relapsed/refractory diffuse large B‐cell and follicular lymphomas: four year outcomes. Hematol Oncol. 2019;37(suppl S2):137-138. doi: 10.1002/hon.96_2629.</title></titles><dates></dates><urls></urls></record></Cite></EndNote>(2). For comparative purposes, prognosis in this cohort of patients is poor, with a median overall survival of 4.4 months and 1 year overall survival rate of 23%PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYW4gZGVuIE5lc3RlPC9BdXRob3I+PFllYXI+MjAxNjwv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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WYW4gZGVuIE5lc3RlPC9BdXRob3I+PFllYXI+MjAxNjwv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ADDIN EN.CITE.DATA (3). Safety and Toxicity of CAR-T Cell Therapy: Unlike chemotherapy-associated side effects, many of the CAR-T cell toxicities resolve only when cells are done expanding, eradicating, or become exhausted. While toxicities are usually manageable and reversible, national data suggest 5-10% of patients have lethal side-effects within the first three months. There is little data about the long-term side effects of CAR-T cell therapy. Safety concerns include:Immune-mediated rejection of normal tissues that express the targeted antigen: also known as “on-target, off-tumor” response (6). For example, a B-cell aplasia induced by CD-19 targeted CARs.Cytokine release syndrome (CRS): high fevers, hypotension, hypoxia, and toxicity of any organ that usually occurs within the first week after CAR-T infusion (8). It is likely due to intense anti-tumor responses by activated T cells. While CRS can bring one to the brink of critical illness, it is usually fully reversible. CRS is common, with rates between 37-93%. Most patients who experience a durable response from CAR-T therapy exhibit at least some degree of CRS, so its presence is interpreted as a good prognostic sign. Patients at high risk of severe CRS include those with bulky tumor burden, comorbidities, and those who develop CRS within 3 days of cell infusion PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYXVkZTwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl
Y051bT41NzE5PC9SZWNOdW0+PERpc3BsYXlUZXh0Pig0KTwvRGlzcGxheVRleHQ+PHJlY29yZD48
cmVjLW51bWJlcj41NzE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk
Yi1pZD0ienp2ZnhhYXdlcnRmd2xlYWY5YXg5c3o0ZTlkcHcycGF0enZ4IiB0aW1lc3RhbXA9IjE1
NzQ4MDczNDQiIGd1aWQ9ImU1NDAwZjdlLWI4MWItNDJlYS1hMGM3LTg4MzE1NjAyOTQ2MCI+NTcx
OTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3
PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWF1ZGUsIFMuIEwuPC9h
dXRob3I+PGF1dGhvcj5GcmV5LCBOLjwvYXV0aG9yPjxhdXRob3I+U2hhdywgUC4gQS48L2F1dGhv
cj48YXV0aG9yPkFwbGVuYywgUi48L2F1dGhvcj48YXV0aG9yPkJhcnJldHQsIEQuIE0uPC9hdXRo
b3I+PGF1dGhvcj5CdW5pbiwgTi4gSi48L2F1dGhvcj48YXV0aG9yPkNoZXcsIEEuPC9hdXRob3I+
PGF1dGhvcj5Hb256YWxleiwgVi4gRS48L2F1dGhvcj48YXV0aG9yPlpoZW5nLCBaLjwvYXV0aG9y
PjxhdXRob3I+TGFjZXksIFMuIEYuPC9hdXRob3I+PGF1dGhvcj5NYWhua2UsIFkuIEQuPC9hdXRo
b3I+PGF1dGhvcj5NZWxlbmhvcnN0LCBKLiBKLjwvYXV0aG9yPjxhdXRob3I+UmhlaW5nb2xkLCBT
LiBSLjwvYXV0aG9yPjxhdXRob3I+U2hlbiwgQS48L2F1dGhvcj48YXV0aG9yPlRlYWNoZXksIEQu
IFQuPC9hdXRob3I+PGF1dGhvcj5MZXZpbmUsIEIuIEwuPC9hdXRob3I+PGF1dGhvcj5KdW5lLCBD
LiBILjwvYXV0aG9yPjxhdXRob3I+UG9ydGVyLCBELiBMLjwvYXV0aG9yPjxhdXRob3I+R3J1cHAs
IFMuIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RnJv
bSB0aGUgRGl2aXNpb24gb2YgT25jb2xvZ3ksIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBvZiBQ
aGlsYWRlbHBoaWEgKFMuTC5NLiwgUi5BLiwgRC5NLkIuLCBOLkouQi4sIFMuUi5SLiwgRC5ULlQu
LCBTLkEuRy4pLCB0aGUgRGVwYXJ0bWVudHMgb2YgUGVkaWF0cmljcyAoUy5MLk0uLCBSLkEuLCBE
Lk0uQi4sIE4uSi5CLiwgUy5SLlIuLCBELlQuVC4sIFMuQS5HLiksIEJpb3N0YXRpc3RpY3MgYW5k
IEVwaWRlbWlvbG9neSAoUC5BLlMuLCBSLkEuKSwgYW5kIFBhdGhvbG9neSBhbmQgTGFib3JhdG9y
eSBNZWRpY2luZSAoSi5KLk0uLCBCLkwuTC4sIEMuSC5KLiwgUy5BLkcuKSwgdGhlIERpdmlzaW9u
IG9mIEhlbWF0b2xvZ3ktT25jb2xvZ3kgKE4uRi4sIEQuTC5QLiksIGFuZCBBYnJhbXNvbiBDYW5j
ZXIgQ2VudGVyIChOLkYuLCBBLkMuLCBWLkUuRy4sIFouWi4sIFMuRi5MLiwgWS5ELk0uLCBKLkou
TS4sIEIuTC5MLiwgQy5ILkouLCBELkwuUC4sIFMuQS5HLiksIFBlcmVsbWFuIFNjaG9vbCBvZiBN
ZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBQZW5uc3lsdmFuaWEgLSBhbGwgaW4gUGhpbGFkZWxwaGlh
OyBhbmQgTm92YXJ0aXMgUGhhcm1hY2V1dGljYWxzLCBFYXN0IEhhbm92ZXIsIE5KIChBLlMuKS48
L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5DaGltZXJpYyBhbnRpZ2VuIHJlY2VwdG9yIFQg
Y2VsbHMgZm9yIHN1c3RhaW5lZCByZW1pc3Npb25zIGluIGxldWtlbWlhPC90aXRsZT48c2Vjb25k
YXJ5LXRpdGxlPk4gRW5nbCBKIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2Rp
Y2FsPjxmdWxsLXRpdGxlPk4gRW5nbCBKIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBh
Z2VzPjE1MDctMTc8L3BhZ2VzPjx2b2x1bWU+MzcxPC92b2x1bWU+PG51bWJlcj4xNjwvbnVtYmVy
PjxlZGl0aW9uPjIwMTQvMTAvMTY8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2Nl
bnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWJvZGllcywg
TW9ub2Nsb25hbCwgSHVtYW5pemVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD4q
QW50aWdlbnMsIENEMTk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+
Q2hpbGQsIFByZXNjaG9vbDwva2V5d29yZD48a2V5d29yZD5DaGltZXJhPC9rZXl3b3JkPjxrZXl3
b3JkPkN5dG9raW5lcy9ibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtl
eXdvcmQ+R2VuZXRpYyBFbmdpbmVlcmluZzwva2V5d29yZD48a2V5d29yZD4qR2VuZXRpYyBUaGVy
YXB5PC9rZXl3b3JkPjxrZXl3b3JkPkdlbmV0aWMgVmVjdG9yczwva2V5d29yZD48a2V5d29yZD5I
dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+KkltbXVub3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+
TGVudGl2aXJ1cy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3
b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWN1cnNvciBDZWxsIEx5bXBob2Js
YXN0aWMgTGV1a2VtaWEtTHltcGhvbWEvaW1tdW5vbG9neS9tb3J0YWxpdHkvKnRoZXJhcHk8L2tl
eXdvcmQ+PGtleXdvcmQ+UmVjZXB0b3JzLCBBbnRpZ2VuLCBULUNlbGwvZ2VuZXRpY3MvKnRoZXJh
cGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5SZWN1cnJlbmNlPC9rZXl3b3JkPjxrZXl3b3Jk
PlJlbWlzc2lvbiBJbmR1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5
d29yZD48a2V5d29yZD5ULUx5bXBob2N5dGVzLyppbW11bm9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk
PllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+
PHB1Yi1kYXRlcz48ZGF0ZT5PY3QgMTY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4x
NTMzLTQ0MDYgKEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9pc2JuPjxhY2Nl
c3Npb24tbnVtPjI1MzE3ODcwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVy
bD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNTMxNzg3MDwvdXJsPjwvcmVs
YXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM0MjY3NTMxPC9jdXN0b20yPjxlbGVjdHJvbmlj
LXJlc291cmNlLW51bT4xMC4xMDU2L05FSk1vYTE0MDcyMjI8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut
bnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYXVkZTwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl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ADDIN EN.CITE.DATA (4). The rates of severe CRS are 1-23% for patients with lymphoma and 23-46% for patients with ALL, with nearly half of those enrolled in the early CAR-T trials requiring intensive care management PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYW50b21hc3NvPC9BdXRob3I+PFllYXI+MjAxOTwvWWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TYW50b21hc3NvPC9BdXRob3I+PFllYXI+MjAxOTwvWWVh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ADDIN EN.CITE.DATA (5). Management of severe CRS remains challenging, given the delicate balance of mitigating uncontrolled inflammation without dampening antitumor efficacy. While oncologists may try to avoid corticosteroids to preserve antitumor efficacy, they may be necessary for severe cases as may vasopressors and specialized medications such as tocilizumab or anakinra PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48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ADDIN EN.CITE.DATA (6). CAR-T-cell related immune effector cell-associated neurotoxicity syndrome (ICANS) is characterized by global encephalopathy, aphasia, seizure/seizure-like activity, obtundation, tremor/myoclonus, and hallucinations PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZWVsYXB1PC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48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ADDIN EN.CITE.DATA (6). Rates of severe ICANS are 12–30% for patients with lymphoma and 13–42% for patients with leukemia. Clinical factors impacting the risk of ICANS include marrow disease, higher CAR T-cell dose, prior severe CRS, and pre-existing neurologic comorbidities. While ICANS is often reversible, permanent neurologic side-effects and fatalities have resulted from ICANS.Cost: The price of CAR T-cell therapy approximates $500,000 ADDIN EN.CITE <EndNote><Cite><Author>Green</Author><Year>2018</Year><RecNum>5731</RecNum><DisplayText>(7)</DisplayText><record><rec-number>5731</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1577127136" guid="f2de69b3-1043-403b-be1d-78560469f483">5731</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Green, A. K.</author><author>Saltz, L. B.</author></authors></contributors><auth-address>Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA</auth-address><titles><title>Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs</title><secondary-title>Journal of Clinical Oncology</secondary-title><alt-title>J Clin Oncol</alt-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><alt-periodical><full-title>J Clin Oncol</full-title></alt-periodical><pages>1381-1382</pages><volume>36</volume><number>13</number><dates><year>2018</year><pub-dates><date>May 1</date></pub-dates></dates><isbn>0732-183x</isbn><accession-num>WOS:000433528700019</accession-num><urls><related-urls><url><Go to ISI>://WOS:000433528700019</url></related-urls></urls><electronic-resource-num>10.1200/Jco.2018.78.4397</electronic-resource-num><language>English</language></record></Cite></EndNote>(7). This does not include the cost of inpatient monitoring and toxicity management, which can add hundreds of thousand dollars. Insurance coverage for the treatment varies with many payers making coverage decisions on a case-by-case basis. Even when payers cover the cost of treatment, however, patients often are responsible for expenses such as travel, copays, etc. From a national health care perspective, CAR-T costs have been manageable because the eligible population for CAR-T remains small. If CAR-T demonstrates benefit across a broader range of malignancies, it might be used in millions, raising cost concerns for health systems ADDIN EN.CITE <EndNote><Cite><Author>Green</Author><Year>2018</Year><RecNum>5731</RecNum><DisplayText>(7)</DisplayText><record><rec-number>5731</rec-number><foreign-keys><key app="EN" db-id="zzvfxaawertfwleaf9ax9sz4e9dpw2patzvx" timestamp="1577127136" guid="f2de69b3-1043-403b-be1d-78560469f483">5731</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Green, A. K.</author><author>Saltz, L. B.</author></authors></contributors><auth-address>Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA</auth-address><titles><title>Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs</title><secondary-title>Journal of Clinical Oncology</secondary-title><alt-title>J Clin Oncol</alt-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><alt-periodical><full-title>J Clin Oncol</full-title></alt-periodical><pages>1381-1382</pages><volume>36</volume><number>13</number><dates><year>2018</year><pub-dates><date>May 1</date></pub-dates></dates><isbn>0732-183x</isbn><accession-num>WOS:000433528700019</accession-num><urls><related-urls><url><Go to ISI>://WOS:000433528700019</url></related-urls></urls><electronic-resource-num>10.1200/Jco.2018.78.4397</electronic-resource-num><language>English</language></record></Cite></EndNote>(7). Prognostic Uncertainty: Although treatment carries quality of life, morbidity, and mortality risks, many patients face almost certain death without CAR-T. Also, it can be challenging to identify which patients will/will not have durable responses. Advance care planning is therefore nuanced given the prognostic uncertainty, and the unique nature of a binary outcome. This differs from our traditional understanding of disease trajectory for advanced malignancies. It is important to balance the hope for a good response, with the realization that good outcomes are not guaranteed and rapid trajectory to end-of-life is possible. References: ADDIN EN.REFLIST 1.Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31-46.2.Chong EA, Svoboda J, Nasta SD, et al. CD19‐directed car t cell therapy (CTL019) for relapsed/refractory diffuse large B‐cell and follicular lymphomas: four year outcomes. Hematol Oncol. 2019;37(suppl S2):137-138. doi: 10.1002/hon.96_2629.3.Van den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplantation. 2016;51(1):51-7.4.Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17.5.Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book. 2019;39:433-44.6.Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.7.Green AK, Saltz LB. Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. Journal of Clinical Oncology. 2018;36(13):1381-2.Authors’ Affiliations: Johns Hopkins Medicine, Baltimore, MD; Massachusetts General Hospital, Boston, MA.Conflicts of Interest: The authors declare that they have no conflict of interest. Version History: First electronically published in March 2020. Originally edited by Sean Marks MD.Fast Facts and Concepts are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual Fast Fact are solely responsible for that Fast Fact’s content. The full set of Fast Facts are available at Palliative Care Network of Wisconsin with contact information, and how to reference Fast Facts.Copyright: All Fast Facts and Concepts are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (). Fast Facts can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a Fast Fact, let us know!Disclaimer: Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- examples of facts and opinions
- palliative care versus home health
- palliative care home health regulations
- palliative care criteria checklist
- harvard cme primary care 2020
- palliative care protocols for hospitals
- what does palliative care provide
- palliative care documentation requirements
- palliative care eligibility criteria
- palliative care satisfaction survey tool
- example of palliative care orders
- palliative care guidelines nursing homes